Berberol P Compared With Berberol K for Mildly to Moderately High Cholesterol
Compares two Berberol supplements for lowering cholesterol in adults with high cholesterol.
Plain-language title generated from the registry record
Registry title: Berberol P for Mild-to-Moderate Hypercholesterolaemia
Key facts
- Where
- Guidonia Montecelio, Piacenza, Rome, and Urbino, ItalySee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07789366, who can take part
Where in Italy
- EuromedGuidonia Montecelio, ItalyNo longer taking part
- Poliambulatorio HealthPiacenza, ItalyNo longer taking part
- EndomedRome, ItalyNo longer taking part
- University of Urbino Carlo BoUrbino, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Liaquat University of Medical & Health Sciences
- Trial code
- NCT07789366
- Record updated
- 27 August 2026
- Original description
This randomized, controlled, multicentre clinical trial will evaluate the efficacy and safety of Berberol® P compared with Berberol® K in adults with mild-to-moderate hypercholesterolaemia.Read full original descriptionShow less
A Randomized, Controlled, Multicentre, Three-Arm Clinical Trial to Evaluate the Efficacy and Safety of Berberol® P Compared With Berberol® K in Adults With Mild-to-Moderate Hypercholesterolaemia
This randomized, controlled, multicentre clinical trial will evaluate the efficacy and safety of Berberol® P compared with Berberol® K in adults with mild-to-moderate hypercholesterolaemia.
A total of 255 participants will be randomized in a 1:1:1 ratio to receive Berberol® P 1 tablet daily, Berberol® P 2 tablets daily, or Berberol® K 1 tablet daily for 12 weeks. The study will primarily assess whether Berberol® P is non-inferior to Berberol® K in reducing low-density lipoprotein cholesterol (LDL-C). Changes in other lipid parameters, glucose metabolism, anthropometric measures, blood pressure, and safety will also be evaluated.
Inclusion: Age 18-70 years; Male or female; LDL-C 115-190 mg/dL and/or total cholesterol 200-260 mg/dL; Triglycerides <400 mg/dL; Willingness to maintain stable diet and physical activity; Written informed consent for study participation obtained prior to the start of the study.
Exclusion: Use of statins, ezetimibe, fibrates, PCSK9 inhibitors, or lipid-lowering nutraceuticals within 30 days prior to enrollment; Alcohol or drug abuse; Participation in another clinical trial within 30 days prior to enrollment; Uncontrolled diabetes; Significant liver or kidney disease; Pregnancy or breastfeeding; Known intolerance to any component of the study products; Recent cardiovascular events; Lack of written informed consent.